Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Histologically confirmed newly diagnosed hepatoblastoma~* Standard risk hepatoblastoma (Pretext I,II,III)~* Age ≤ 18 years and \> 1 month~* Written informed consent and national/local ethics committee and regulatory approval~* Centre/country willing and able to organise audiometry at the minimum required quality standard and to provide the contact details of the Consultant Audiologist or Ear Nose and Throat Surgeon who will take the responsibility for seeing that this is done~* Ability to comply with requirements for submission of material for central review~* For females of child-bearing potential, a negative pregnancy test prior to study treatment is required.~* Any patient who is of reproductive age should agree to use adequate contraception for the duration of the trial.~Exclusion:~High risk hepatoblastoma~* Hepatocellular carcinoma~* Treatment starting more than 15 days from written biopsy report~* Abnormal renal function~* Any previous chemotherapy~* Recurrent disease~* Previous hypersensitivity to STS~* Patient unable to follow the protocol for any reason

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (cisplatin) (Type: ACTIVE_COMPARATOR): Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (cisplatin + STS) (Type: EXPERIMENTAL): Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).